To assess the diagnostic utility of salivary lactoferrin in AD patients, González-Sánchez et al. examined the relationship between salivary lactoferrin and cerebral Aβ load using Amyloid-Positron-Emission Tomography (PET) neuroimaging in two different cross-sectional cohorts including 52 healthy asymptomatic subjects considered as controls, 21 MCI due to AD, 25 with AD dementia and 18 with frontotemporal dementia (FTD). Here, LTF is linked to frontotemporal dementia.